24/7 Market News Snapshot 11 Dec, 2023 – IN8bio Inc (NYSE: INAB)

December 12, 2023

DENVER, Colo., 11 Dec, 2023 (247marketnews.com) – IN8bio Inc (Nasdaq:INAB), a clinical-stage biopharmaceutical company specializing in innovative gamma-delta T cell therapies, experienced a significant bullish price movement today, indicating market confidence in its potential. The stock price surged by $1.28, marking a remarkable increase of 29.29%. This surge was supported by high trading volume, with 3,831,856 shares changing hands.

In addition to the exciting stock movement, IN8bio Inc announced groundbreaking data from its Phase 1 investigator-sponsored trial of INB-100. The trial focused on patients with hematologic malignancies and has shown promising results. In this trial, all ten evaluable leukemia patients treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of November 3, 2023. This exceptional outcome represents a significant potential breakthrough in the treatment of high-risk or relapsed acute myeloid leukemia (AML) and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT).

Based on these positive findings, the trial will be expanded, with an additional ten patients enrolled at Dose Level (DL) 2, the recommended Phase 2 dose (RP2D). The decision to expand the trial reflects the confidence in INB-100’s efficacy and its favorable benefit/risk profile.

Dr. Jane Johnson, Chief Medical Officer at IN8bio, Inc., expressed her enthusiasm, stating, “We are thrilled with the success that the Phase 1 trial has demonstrated thus far. The data clearly indicates the ability of INB-100 to provide durable complete remissions, which is a major milestone in the treatment of high-risk or relapsed AML and other hematologic malignancies.”

These remarkable findings from the Phase 1 trial will be presented at the renowned 65th ASH Annual Meeting & Exposition, scheduled for this evening. IN8bio, Inc. looks forward to sharing the potentially game-changing implications of these results with the broader scientific and medical community.

Further updated data from the trial will be presented at upcoming medical meetings in 2024, as IN8bio, Inc. continues to gather more valuable insights into the efficacy of INB-100. This announcement signifies a significant advancement in cancer therapeutics and reinforces the company’s commitment to developing life-changing treatments for patients. The positive results from the Phase 1 trial demonstrate the potential of INB-100 to redefine the standard of care for high-risk or relapsed AML and other hematologic malignancies.

Connect with 24/7 Market News:
247marketnews.com

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (INAB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.